Literature DB >> 2386110

Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue.

G Hochhaus1, H W Moellmann.   

Abstract

The relative binding affinities (RBA) of two locally used glucocorticoids, rimexolone and flunisolide have been measured for the glucocorticoid receptor of human synovial tissue. The non-fluorinated derivative rimexolone exhibited a binding affinity (RBA of 130) somewhat higher than that of dexamethasone (RBA of 100) but lower than that of flunisolide (RBA 190). Potential metabolites of rimexolone hydroxolated at the C17 side-chain, showed decreased binding affinities, while the 6-hydroxy metabolite of rimexolone and flunisolide (its main metabolite) and the 4,5-dihydro metabolites of rimexolone hardly bound at all. These results support previous pharmacological findings that the high ratio of local to systemic effects of both compounds are due to a pronounced receptor affinity of the parent compounds and the fast systemic metabolism to derivatives with low pharmacodynamic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386110     DOI: 10.1007/bf01966302

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  11 in total

1.  Nature of steroid-glucocorticoid receptor interactions: thermodynamic analysis of the binding reaction.

Authors:  M E Wolff; J D Baxter; P A Kollman; D L Lee; I D Kuntz; E Bloom; D T Matulich; J Morris
Journal:  Biochemistry       Date:  1978-08-08       Impact factor: 3.162

2.  Identification of glucocorticoid receptors in normal and neoplastic adult human lung.

Authors:  G Hochhaus; P Rohdewald; H Möllmann; D Greschuchna
Journal:  Res Exp Med (Berl)       Date:  1983

3.  The biological properties of Org 6216, a new type of steroid with a selective local anti-inflammatory action.

Authors:  P K Fox; A J Lewis; R M Rae; A W Sim; G F Woods
Journal:  Arzneimittelforschung       Date:  1980

4.  The local anti-inflammatory activity of rimexolone (Org 6216) in fibrin-induced monoarticular arthritis and adjuvant-induced arthritis.

Authors:  A J Lewis
Journal:  Agents Actions       Date:  1980-06

5.  Competitive binding assay for glucocorticoids. Influence of experimental conditions on measurement of the affinity of competitive steroids for the receptor.

Authors:  A Weisz; T W Hutchens; F S Markland
Journal:  J Steroid Biochem       Date:  1982-04       Impact factor: 4.292

6.  Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids.

Authors:  E Dahlberg; A Thalén; R Brattsand; J A Gustafsson; U Johansson; K Roempke; T Saartok
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

7.  Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21-esters.

Authors:  M Pörtner; H Möllmann; P Rohdewald
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

8.  The persistence and effects of rimexolone in arthritic and normal rabbit knee joints.

Authors:  H Nieuwenhuyse; A J Lewis
Journal:  Arzneimittelforschung       Date:  1980

9.  Flunisolide metabolism and dynamics of a metabolite.

Authors:  M D Chaplin; W Rooks; E W Swenson; W C Cooper; C Nerenberg; N I Chu
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

10.  Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.

Authors:  T Ojasoo; J C Doré; J Gilbert; J P Raynaud
Journal:  J Med Chem       Date:  1988-06       Impact factor: 7.446

View more
  2 in total

Review 1.  Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Authors:  M Schäfer-Korting; M H Schmid; H C Korting
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

2.  Significant receptor affinities of metabolites and a degradation product of mometasone furoate.

Authors:  Anagnostis Valotis; Petra Högger
Journal:  Respir Res       Date:  2004-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.